ulcerative proctosigmoiditis.

October 27, 2017October 27, 2017

Innovation Readies Next Clinical Phase for Investigational IBD Therapy Brilacidin

News

Innovation Pharmaceuticals, a clinical-stage biopharmaceutical company, issued an update on its research program for Brilacidin, an investigational non-corticosteroid and anti-inflammatory therapy for inflammatory bowel disease (IBD). The company is planning ... Read more

June 27, 2017

Treatment Ends in Trial Showing That Brilacidin Is Effective Against Bowel Disease

News

Treatment has been completed in a Phase 2 clinical trial of brilacidin for ulcerative proctitis and ulcerative proctosigmoiditis — a study that led to six of the 12 patients’ bowel ... Read more

February 27, 2017

Cellceutix’s IBD Therapy Brilacidin Progresses to Highest Dose Group in Phase 2 Trial

News

Cellceutix says the ongoing Phase 2 clinical trial of its lead drug candidate Brilacidin has progressed to its third cohort (highest dose) to induce remission of mild-to-moderate ulcerative colitis, now that the study’s Safety Committee has ... Read more

December 9, 2016

Cellceutix Initiates Dose Escalation in Phase 2 Trial of Brilacidin for Ulcerative Proctitis

News

Cellceutix has initiated the dose escalation of brilacidin (PMX-30063) in the second cohort of patients enrolled in a Phase 2 clinical trial evaluating the drug candidate for the treatment of ulcerative ... Read more

January 27, 2015January 27, 2015

Cellceutix Seeks FDA’s Advice on Ulcerative Proctitis Therapy

News

Clinical stage biopharmaceutical company, Cellceutix Corporation, is submitting a request to the U.S. Food and Drug Administration (FDA) for a pre-Investigational New Drug (IND) meeting. The company, which is dedicated to developing novel treatments with oncology, ... Read more